Skip to main content
. 2021 Jun 28;42(5):528–583. doi: 10.1210/endrev/bnab021

Table 5.

Coefficient of variation (%) for selected β-cell function measures obtained using oral and intravenous testing in humans

NGT IGT Diabetes Diabetes (no meds) All Reference
Oral glucose tolerance test (OGTT)
Fasting glucose 4.0 5.2 4.3 4.8 4.5 (478)
2-hour glucose 24.9 11.0 8.0 5.9 -- (478)
Fasting insulin 19.3 14.3 16.5 17.1 16.6 (478)
Fasting C-peptide 11.5 10.8 7.2 8.3 9.7 (478)
HOMA-IR 19.1 14.4 16.1 17.0 16.4 (478)
∆Insulin0-30/∆glucose0-30 41.1 62.9 69.1 79.7 57.1 (478)
∆C-peptide0-30/∆glucose0-30 42.3 37.4 27.3 32.3 34.7 (478)
IncAUCinsulin/IncAUCglucose 29.4 27.0 19.2 22.7 24.9 (478)
IncAUCC-peptide/IncAUCglucose 25.5 14.2 10.0 9.0 17.7 (478)
Model-derived parameters from an oral glucose tolerance test (OGTT)
Glucose sensitivity a 17.2 16.5 20.3 20.3 20.3 (478)
Rate sensitivity a 42.1 40.5 114.8 76.2 44.6 (478)
Potentiation a 43.6 26.7 26.9 26.1 33.0 (478)
φ db 31 (493)
φ sb 18 (493)
Intravenous glucose tolerance test (IVGTT)
AIRglucose (first-phase insulin response) 20.6 -- -- -- -- (494)
20.1 -- -- -- -- (495)
Kg (glucose disappearance constant) 14.5 -- -- -- -- (494)
51.4 -- -- -- -- (495)
SI (insulin sensitivity index)c 16.9 -- -- -- -- (494)
20.2 -- -- -- -- (495)
Hyperglycemic clamp
Fasting insulin 13.2 -- -- -- -- (496)
AIRglucose (first-phase insulin response) 10.4 -- -- -- -- (496)
Maximal insulin response to arginine 16.3 -- -- -- -- (496)

Abbreviations: AIRglucose, acute insulin response to glucose; ∆C-peptide0-30/∆C-peptide0-30, C-peptide index; ∆Insulin0-30/∆glucose0-30, insulinogenic index; IncAUC, incremental area under the curve; Kg, glucose disappearance constant.

a calculated using a model developed by Mari and colleagues (486)

b calculated using a model developed by Cobelli and colleagues (487)

c calculated using the minimal model of glucose kinetics developed by Bergman and colleagues (108)